BRISTOL-MYERS SQUIBB CO (1BMY.MI) Stock Price, Forecast & Analysis
BIT:1BMY • US1101221083
1BMY.MI Key Statistics, Chart & Performance
The current stock price of 1BMY.MI is 51.43 EUR. In the past month the price decreased by -11.13%.
1BMY.MI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 1BMY.MI.
1BMY.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to 1BMY.MI. While 1BMY.MI belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
1BMY.MI Financial Highlights
Over the last trailing twelve months 1BMY.MI reported a non-GAAP Earnings per Share(EPS) of 5.21. The EPS increased by 439.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.64% | ||
| ROA | 7.83% | ||
| ROE | 38.19% | ||
| Debt/Equity | 2.33 |
1BMY.MI Forecast & Estimates
34 analysts have analysed 1BMY.MI and the average price target is 52.72 EUR. This implies a price increase of 2.5% is expected in the next year compared to the current price of 51.43.
For the next year, analysts expect an EPS growth of -1.05% and a revenue growth -1.88% for 1BMY.MI
1BMY.MI Ownership
1BMY.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SAN | SANOFI | 9.72 | 198.536B | ||
| 1SAN | SANOFI | 9.72 | 198.488B | ||
| SNW | SANOFI | 9.72 | 198.464B | ||
| MRK | MERCK KGAA | 14.86 | 55.543B | ||
| UNC | UCB SA | 26.34 | 52.693B | ||
| UCB | UCB SA | 24.53 | 49.075B | ||
| 1BAYN | BAYER AG-REG | 8.6 | 41.291B | ||
| BAYN | BAYER AG-REG | 8.6 | 41.272B | ||
| IPN | IPSEN | 14.47 | 13.837B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.69 | 10.126B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1BMY.MI
Company Profile
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 32,500 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Company Info
BRISTOL-MYERS SQUIBB CO
Route 206 And Province Line Road
Princeton NEW JERSEY US
Employees: 34100
Phone: 13026587581
BRISTOL-MYERS SQUIBB CO / 1BMY.MI FAQ
Can you describe the business of BRISTOL-MYERS SQUIBB CO?
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 32,500 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Can you provide the latest stock price for BRISTOL-MYERS SQUIBB CO?
The current stock price of 1BMY.MI is 51.43 EUR. The price increased by 0.8% in the last trading session.
What is the dividend status of BRISTOL-MYERS SQUIBB CO?
BRISTOL-MYERS SQUIBB CO (1BMY.MI) has a dividend yield of 4.12%. The yearly dividend amount is currently 2.13.
How is the ChartMill rating for BRISTOL-MYERS SQUIBB CO?
1BMY.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Can you provide the growth outlook for BRISTOL-MYERS SQUIBB CO?
The Revenue of BRISTOL-MYERS SQUIBB CO (1BMY.MI) is expected to decline by -1.88% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of 1BMY stock?
BRISTOL-MYERS SQUIBB CO (1BMY.MI) has a market capitalization of 104.70B EUR. This makes 1BMY.MI a Large Cap stock.
What is the next earnings date for 1BMY stock?
BRISTOL-MYERS SQUIBB CO (1BMY.MI) will report earnings on 2026-04-30.